Upstream Bio (NASDAQ:UPB) Shares Down 10.3% – What’s Next?

Upstream Bio, Inc. (NASDAQ:UPB) was down 10.3% during mid-day trading on Thursday . The company traded as low as $13.42 and last traded at $13.1760. Approximately 804,962 shares changed hands during trading, a decline of 12% from the average daily volume of 910,805 shares. The stock had previously closed at $14.69.

Analyst Upgrades and Downgrades

Several research firms have weighed in on UPB. Mizuho raised shares of Upstream Bio to a “strong-buy” rating in a report on Thursday, December 18th. Evercore assumed coverage on Upstream Bio in a report on Tuesday, November 18th. They set an “outperform” rating and a $40.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Upstream Bio in a report on Wednesday, January 21st. Finally, Lifesci Capital started coverage on Upstream Bio in a research report on Tuesday, December 2nd. They set an “outperform” rating and a $43.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $45.25.

Upstream Bio Stock Down 12.9%

The stock has a 50 day moving average of $28.93 and a 200 day moving average of $23.29. The firm has a market cap of $691.71 million, a price-to-earnings ratio of -6.81 and a beta of 1.90.

Institutional Investors Weigh In On Upstream Bio

Large investors have recently modified their holdings of the business. GF Fund Management CO. LTD. bought a new position in shares of Upstream Bio in the fourth quarter worth about $29,000. Torren Management LLC bought a new position in shares of Upstream Bio in the 4th quarter valued at $30,000. BNP Paribas Financial Markets boosted its holdings in shares of Upstream Bio by 229.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,097 shares of the company’s stock valued at $34,000 after acquiring an additional 2,158 shares in the last quarter. Legal & General Group Plc increased its holdings in Upstream Bio by 83.0% in the 2nd quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock worth $35,000 after purchasing an additional 1,440 shares in the last quarter. Finally, CWM LLC raised its position in Upstream Bio by 107.5% in the second quarter. CWM LLC now owns 3,312 shares of the company’s stock valued at $36,000 after purchasing an additional 1,716 shares during the last quarter.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.